A Clinical Quantitative Evaluation of Hepatobiliary Transport of [11C]Dehydropravastatin in Humans Using Positron Emission Tomography
暂无分享,去创建一个
Kazuya Maeda | Yuichi Sugiyama | Yasuyoshi Watanabe | Hideki Kawahata | Takashi Yamanaga | Joji Kawabe | Susumu Shiomi | Yilong Cui | Hiroyuki Kusuhara | Kota Toshimoto | Takayoshi Nakaoka | Akira Ishii | Yasuyoshi Watanabe | K. Maeda | H. Kusuhara | Y. Sugiyama | N. Kawada | Masaaki Tanaka | Takayoshi Nakaoka | K. Kaneko | Satsuki Irie | Yasuhiro Wada | Hideki Kawahata | J. Kawabe | A. Ishii | Yilong Cui | E. Kawamura | Masaaki Tanaka | Yasuhiro Wada | K. Toshimoto | S. Shiomi | Ken-ichi Kaneko | Yumiko Katayama | Satsuki Irie | Takeshi Miyake | Masaru Enomoto | Etsushi Kawamura | Norifumi Kawada | M. Enomoto | Takashi Yamanaga | Yumiko Katayama | T. Miyake
[1] P. Bosma,et al. Gene Replacement Therapy for Genetic Hepatocellular Jaundice , 2015, Clinical Reviews in Allergy & Immunology.
[2] V. Sasseville,et al. A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2) , 1999, The Journal of Biological Chemistry.
[3] Y. Sugiyama,et al. Primary active transport of organic anions on bile canalicular membrane in humans. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[4] Kazuya Maeda,et al. PET Imaging–Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me , 2012, The Journal of Nuclear Medicine.
[5] Yasuyoshi Watanabe,et al. Evaluation of Breast Cancer Resistance Protein Function in Hepatobiliary and Renal Excretion Using PET with 11C-SC-62807 , 2013, The Journal of Nuclear Medicine.
[6] Y. Sugiyama,et al. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.
[7] K. Maeda,et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.
[8] G Blomqvist,et al. Kinetic analysis. , 1991, Wiener klinische Wochenschrift.
[9] D. Keppler,et al. The apical conjugate efflux pump ABCC2 (MRP2) , 2007, Pflügers Archiv - European Journal of Physiology.
[10] H. Hsu,et al. Neonatal Dubin-Johnson Syndrome: Long-Term Follow-up and MRP2 Mutations Study , 2006, Pediatric Research.
[11] F. Johnson,et al. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. , 1954, Medicine.
[12] Kazuya Maeda,et al. Identification of the Hepatic Efflux Transporters of Organic Anions Using Double-Transfected Madin-Darby Canine Kidney II Cells Expressing Human Organic Anion-Transporting Polypeptide 1B1 (OATP1B1)/Multidrug Resistance-Associated Protein 2, OATP1B1/Multidrug Resistance 1, and OATP1B1/Breast Cancer R , 2005, Journal of Pharmacology and Experimental Therapeutics.
[13] S. Singhvi,et al. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects. , 1990, British journal of clinical pharmacology.
[14] Y. Sugiyama,et al. Species differences in the transport activity for organic anions across the bile canalicular membrane. , 1999, The Journal of pharmacology and experimental therapeutics.
[15] Yi Wang,et al. Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin , 2008, Drug Metabolism and Disposition.
[16] Kazuya Maeda,et al. Positron Emission Tomography Studies Using (15R)-16-m-[11C]tolyl-17,18,19,20-tetranorisocarbacyclin Methyl Ester for the Evaluation of Hepatobiliary Transport , 2010, Journal of Pharmacology and Experimental Therapeutics.
[17] D. Surry,et al. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[18] K. Oda,et al. [PET Imaging]. , 2009, Nihon Hoshasen Gijutsu Gakkai zasshi.
[19] J. Link,et al. PET imaging of Oatp-mediated hepatobiliary transport of [(11)C] rosuvastatin in the rat. , 2014, Molecular pharmaceutics.
[20] P. Neuvonen,et al. Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects. , 2003, British journal of clinical pharmacology.
[21] G. Muehllehner,et al. Positron emission tomography , 2006, Physics in medicine and biology.
[22] Yasuyoshi Watanabe,et al. Evaluation of Oatp and Mrp2 Activities in Hepatobiliary Excretion Using Newly Developed Positron Emission Tomography Tracer [11C]Dehydropravastatin in Rats , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[23] H. Kusuhara,et al. Imaging in the Study of Membrane Transporters , 2013, Clinical pharmacology and therapeutics.
[24] K. Maeda,et al. Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments , 2011, Drug Metabolism and Disposition.
[25] K. Maeda,et al. DRUG-DRUG INTERACTION BETWEEN PITAVASTATIN AND VARIOUS DRUGS VIA OATP1B1 , 2006, Drug Metabolism and Disposition.
[26] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[27] K. Maeda. Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs. , 2015, Biological & pharmaceutical bulletin.
[28] Yuichi Sugiyama,et al. Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans , 2010, Journal of Pharmacokinetics and Pharmacodynamics.
[29] Yuichi Sugiyama,et al. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. , 2005, Annual review of pharmacology and toxicology.
[30] Kazuya Maeda,et al. Hepatic and intestinal drug transporters: prediction of pharmacokinetic effects caused by drug-drug interactions and genetic polymorphisms. , 2013, Annual review of pharmacology and toxicology.
[31] Kazuya Maeda,et al. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. , 2008, Drug metabolism and pharmacokinetics.
[32] H. Kusuhara,et al. Effect of Coadministration of Single and Multiple Doses of Rifampicin on the Pharmacokinetics of Fexofenadine Enantiomers in Healthy Subjects , 2013, Drug Metabolism and Disposition.
[33] Yasuyoshi Watanabe,et al. Synthesis of [(11)C]dehydropravastatin, a PET probe potentially useful for studying OATP1B1 and MRP2 transporters in the liver. , 2012, Bioorganic & medicinal chemistry.
[34] Yasuyoshi Watanabe,et al. The involvement of organic anion transporting polypeptide in the hepatic uptake of telmisartan in rats: PET studies with [¹¹C]telmisartan. , 2011, Molecular pharmaceutics.
[35] K. Maeda,et al. Investigation of the Impact of Substrate Selection on In Vitro Organic Anion Transporting Polypeptide 1B1 Inhibition Profiles for the Prediction of Drug-Drug Interactions , 2015, Drug Metabolism and Disposition.
[36] Yasuyoshi Watanabe,et al. [Molecular imaging for drug development]. , 2007, Brain and nerve = Shinkei kenkyu no shinpo.
[37] Y. Sugiyama,et al. Kinetic analysis of in vivo receptor-dependent binding of human epidermal growth factor by rat tissues. , 1988, Journal of pharmaceutical sciences.